BRIEF-Allergan, Amgen collaborating on development, commercialization of four oncology biosimilars
July 21, 2016 at 09:15 AM EDT
* In neoadjuvant phase of study, which included chemotherapy, there were more serious adverse events reported in ABP 980 group
